» Articles » PMID: 36831403

Pixelated Microfluidics for Drug Screening on Tumour Spheroids and Ex Vivo Microdissected Tumour Explants

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2023 Feb 25
PMID 36831403
Authors
Affiliations
Soon will be listed here.
Abstract

Anticancer drugs have the lowest success rate of approval in drug development programs. Thus, preclinical assays that closely predict the clinical responses to drugs are of utmost importance in both clinical oncology and pharmaceutical research. 3D tumour models preserve the tumoral architecture and are cost- and time-efficient. However, the short-term longevity, limited throughput, and limitations of live imaging of these models have so far driven researchers towards less realistic tumour models such as monolayer cell cultures. Here, we present an open-space microfluidic drug screening platform that enables the formation, culture, and multiplexed delivery of several reagents to various 3D tumour models, namely cancer cell line spheroids and ex vivo primary tumour fragments. Our platform utilizes a microfluidic pixelated chemical display that creates isolated adjacent flow sub-units of reagents, which we refer to as fluidic 'pixels', over tumour models in a contact-free fashion. Up to nine different treatment conditions can be tested over 144 samples in a single experiment. We provide a proof-of-concept application by staining fixed and live tumour models with multiple cellular dyes. Furthermore, we demonstrate that the response of the tumour models to biological stimuli can be assessed using the platform. Upscaling the microfluidic platform to larger areas can lead to higher throughputs, and thus will have a significant impact on developing treatments for cancer.

Citing Articles

Next-Generation Microfluidics for Biomedical Research and Healthcare Applications.

Deliorman M, Ali D, Qasaimeh M Biomed Eng Comput Biol. 2023; 14:11795972231214387.

PMID: 38033395 PMC: 10683381. DOI: 10.1177/11795972231214387.


Applications and Advances of Multicellular Tumor Spheroids: Challenges in Their Development and Analysis.

Mitrakas A, Tsolou A, Didaskalou S, Karkaletsou L, Efstathiou C, Eftalitsidis E Int J Mol Sci. 2023; 24(8).

PMID: 37108113 PMC: 10138394. DOI: 10.3390/ijms24086949.

References
1.
Majumder B, Baraneedharan U, Thiyagarajan S, Radhakrishnan P, Narasimhan H, Dhandapani M . Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity. Nat Commun. 2015; 6:6169. PMC: 4351621. DOI: 10.1038/ncomms7169. View

2.
Figueiredo L, Pace R, DArros C, Rethore G, Guicheux J, Le Visage C . Assessing glucose and oxygen diffusion in hydrogels for the rational design of 3D stem cell scaffolds in regenerative medicine. J Tissue Eng Regen Med. 2018; 12(5):1238-1246. DOI: 10.1002/term.2656. View

3.
Qasaimeh M, Ricoult S, Juncker D . Microfluidic probes for use in life sciences and medicine. Lab Chip. 2012; 13(1):40-50. DOI: 10.1039/c2lc40898h. View

4.
Horvath P, Aulner N, Bickle M, Davies A, Del Nery E, Ebner D . Screening out irrelevant cell-based models of disease. Nat Rev Drug Discov. 2016; 15(11):751-769. DOI: 10.1038/nrd.2016.175. View

5.
Hammel J, Cook S, Belanger M, Munson J, Pompano R . Modeling Immunity In Vitro: Slices, Chips, and Engineered Tissues. Annu Rev Biomed Eng. 2021; 23:461-491. PMC: 8277680. DOI: 10.1146/annurev-bioeng-082420-124920. View